SilverOak Wealth Management LLC Increases Stake in Solventum Co. (NYSE:SOLV)

SilverOak Wealth Management LLC lifted its stake in Solventum Co. (NYSE:SOLV) by 5.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 22,559 shares of the company’s stock after buying an additional 1,118 shares during the quarter. SilverOak Wealth Management LLC’s holdings in Solventum were worth $1,490,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Worldquant Millennium Advisors LLC increased its stake in Solventum by 373.6% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock worth $3,323,000 after acquiring an additional 37,600 shares during the last quarter. Harbor Capital Advisors Inc. lifted its position in Solventum by 24.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock valued at $3,103,000 after purchasing an additional 9,333 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Solventum by 37.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock worth $8,217,000 after buying an additional 32,051 shares in the last quarter. State Street Corp raised its position in Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after purchasing an additional 185,938 shares during the period. Finally, Forsta AP Fonden bought a new position in shares of Solventum during the fourth quarter valued at approximately $1,876,000.

Solventum Stock Up 0.0 %

NYSE SOLV opened at $74.27 on Wednesday. The firm’s 50 day moving average price is $70.91 and its 200-day moving average price is $68.88. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Morgan Stanley increased their target price on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Piper Sandler raised their price target on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Finally, Mizuho initiated coverage on shares of Solventum in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective for the company. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Solventum has an average rating of “Hold” and an average price target of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.